In plain words
In the two anxiety trials in the ledger, people taking ashwagandha ended with lower anxiety scores. A US health agency still calls the evidence on anxiety unclear.
The short answer
Both anxiety trials found lower scores with ashwagandha: 40 insomnia patients over 8 weeks (Langade and colleagues, 2020), and stressed healthy adults over 60 days, where it was associated with a lower Hamilton score than placebo (Lopresti and colleagues, 2019); the ledger has no dose for either and no n for the second. A 2014 review reported that two of three earlier placebo-controlled studies found a significant benefit. Three pooled analyses may include these trials, adding no separate evidence. NCCIH (2023) calls the evidence unclear. Certainty is low: only two trials, one with no n in the ledger, and a 2022 pooled analysis rated its evidence low.
Where the evidence sits
Anxiety scores fell
Unclear or no effect
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Langade et al., 2020 | HAM-A improved | Randomized trial | 40 insomnia patients | 8 weeks; dose not in ledger | Not in ledger |
| Lopresti et al., 2019 | HAM-A lower than placebo | Randomized, placebo-controlled | Stressed healthy adults; n not in ledger | 60 days; dose not in ledger | Not in ledger |
| Akhgarjand et al., 2022 | Anxiety lower | Meta-analysis; may include the trials above | 1,002 | Not in ledger | Not in ledger |
| BJPsych Open review, 2025 | Anxiety lower | Meta-analysis; may include the trials above | Not in ledger | Not in ledger | Not in ledger |
| Cheah et al., 2021 | HAM-A lower | Meta-analysis; may include the trials above | 189 | Not in ledger | Not in ledger |
| Pratte et al., 2014 | Benefit in most studies | Review describing earlier studies | Not in ledger | Not in ledger | Not in ledger |
| NCCIH, 2023 | Evidence unclear | Government health summary | None | None | US National Institutes of Health |
| Novella, 2023 | Positives may be false | Blog commentary | None | None | No new data |
HAM-A improved
HAM-A lower than placebo
Anxiety lower
Anxiety lower
HAM-A lower
Benefit in most studies
Evidence unclear
Positives may be false
What did the two anxiety trials find?
Langade and colleagues (2020) reported improved Hamilton Anxiety Rating Scale (HAM-A) scores in 40 insomnia patients over 8 weeks; the ledger has no dose, and no placebo comparison, for this result. Lopresti and colleagues (2019) compared ashwagandha with placebo in stressed healthy adults for 60 days, and the ledger has no n or dose for that trial:
In comparison with the placebo, ashwagandha supplementation was associated with a statistically significant reduction in the HAM-A ( P = .040)
What did earlier studies report?
Pratte and colleagues (2014), writing before both trials above, reported that two of three placebo-controlled studies on the Hamilton scale found a significant benefit and the third came close; the ledger has no n, dose or duration for them. The reviewers added:
Current evidence should be received with caution because of an assortment of study methods and cases of potential bias.
What do the pooled analyses add?
Akhgarjand and colleagues (2022) pooled 12 randomized controlled trials with 1,002 participants, an estimate that may include the trials above, and found lower anxiety than with placebo (SMD -1.55), with high heterogeneity; the ledger has no dose or duration for it. They graded their own result:
Finally, we identified that the certainty of the evidence was low for both outcomes.
Cheah and colleagues (2021) found lower scores too. So did a 2025 BJPsych Open review; both pooled estimates may include the same trials. The ledger has no dose or duration for either.
Why do some sources call it unclear?
NCCIH, part of the US National Institutes of Health, summarized the research in 2023:
However, evidence is unclear about its effects on anxiety.
Steven Novella argued at Science-Based Medicine in 2023, from past anxiety drug research rather than new data, that positive results like these may be false positives until large rigorous trials are done.
Why the sources disagree
The people differ: insomnia patients, stressed healthy adults, and, in the 2025 review, people with mental disorders. The Langade result in the ledger is change over time, while Lopresti's is against placebo. The 2022 pooled estimate, which may include the trials above, had high heterogeneity, and Pratte rated every study it reviewed at unclear or high risk of bias. NCCIH and Novella weigh other people's studies; neither ran one. The ledger has no funding for any study here.
What would settle it
A pre-registered, independently funded trial in about 400 adults with diagnosed anxiety, randomized to a fixed daily dose of one standardized root extract or placebo for 12 weeks, reporting HAM-A against placebo at the end and 4 weeks after stopping. A matching result from a second research group would raise certainty from low to moderate.
How this page was made
The 8 sources are six studies and reviews from a PubMed literature search and two public summaries (NCCIH and Science-Based Medicine). Studies of animals, and of people with schizophrenia or on chemotherapy, were left out, as were claims on sleep, hormones and side effects. Every claim was copied word for word into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 23 Sep 2026, first version, 8 sources.
